Establishment of a non‐alcoholic fatty liver disease model by high fat diet in adult zebrafish
Animal Models and Experimental Medicine · 2024
DOI: 10.1002/ame2.12309 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2024. Verfasst von Xiang Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, School of Public Health, Guangdong Medical University, Zhanjiang, China. Hauptthemen laut MEDLINE: Zebrafish, Non-alcoholic Fatty Liver Disease, Diet, High-Fat, Disease Models, Animal. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Discipline Construction Project of Guangdong Medical University, the Science and Technology Planning Project of Zhanjiang, China.
Abstract (Originalsprache)
Background
Non‐alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in recent years, but the pathogenesis is not fully understood. Therefore, it is important to establish an effective animal model for studying NAFLD.
Methods
Adult zebrafish were fed a normal diet or a high‐fat diet combined with egg yolk powder for 30 days. Body mass index (BMI) was measured to determine overall obesity. Serum lipids were measured using triglyceride (TG) and total cholesterol (TC) kits. Liver lipid deposition was detected by Oil Red O staining. Liver injury was assessed by measuring glutathione aminotransferase (AST) and glutamic acid aminotransferase (ALT) levels. Reactive oxygen species (ROS) and malondialdehyde (MDA) were used to evaluate oxidative damage. The level of inflammation was assessed by qRT‐PCR for pro‐inflammatory factors. H&E staining was used for pathological histology. Caspase‐3 immunofluorescence measured apoptosis. Physiological disruption was assessed via RNA‐seq analysis of genes at the transcriptional level and validated by qRT‐PCR.
Results
The high‐fat diet led to significant obesity in zebrafish, with elevated BMI, hepatic TC, and TG. Severe lipid deposition in the liver was observed by ORO and H&E staining, accompanied by massive steatosis and ballooning. Serum AST and ALT levels were elevated, and significant liver damage was observed. The antioxidant system in the body was severely imbalanced. Hepatocytes showed massive apoptosis. RNA‐seq results indicated that several physiological processes, including endoplasmic reticulum stress, and glucolipid metabolism, were disrupted.
Conclusion
Additional feeding of egg yolk powder to adult zebrafish for 30 consecutive days can mimic the pathology of human nonalcoholic fatty liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nutrition, School of Public Health, Guangdong Medical University, Zhanjiang, China.
- Zhanjiang Key Laboratory of Zebrafish Model for Development and Disease, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
- School of Medical Technology, Guangdong Medical University, Dongguan, China.
ORCID-Profile: Xiang Li, Honghui Guo, Jingjing Zhang
Förderung
- the Discipline Construction Project of Guangdong Medical University
- the Science and Technology Planning Project of Zhanjiang, China
Zitieren
APA
Li, X., Zhou, L., Zheng, Y., He, T., Guo, H., Li, J., & Zhang, J. (2024). Establishment of a non‐alcoholic fatty liver disease model by high fat diet in adult zebrafish. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12309
Vancouver
Li X, Zhou L, Zheng Y, He T, Guo H, Li J, et al. Establishment of a non‐alcoholic fatty liver disease model by high fat diet in adult zebrafish. Animal Models and Experimental Medicine. 2024. doi:10.1002/ame2.12309
BibTeX
@article{Li2024,
author = {Li, Xiang and Zhou, Lei and Zheng, Yuying and He, Taiping and Guo, Honghui and Li, Jiangbin and Zhang, Jingjing},
title = {Establishment of a non‐alcoholic fatty liver disease model by high fat diet in adult zebrafish},
journal = {Animal Models and Experimental Medicine},
year = {2024},
doi = {10.1002/ame2.12309}
}
EUVIMED